| Document |
Document Title |
|
WO/2019/114525A1 |
The present application discloses a plurality of novel derivatives of cucurbitacin B and cucurbitacin E, and salts thereof, and also discloses methods for preparing these novel derivatives. These new derivatives and their salts have comm...
|
|
WO/2019/097434A1 |
The aspects of the present disclosure relates to novel lanosterol derivatives and novel 25-hydroxycholesterol derivatives including their pharmaceutically acceptable salts as well as methods of treatment and pharmaceutical compositions a...
|
|
WO/2019/081586A1 |
The present invention relates to new and improved processes for the preparation of deoxycholic acid (DCA) and pharmaceutically acceptable salts thereof, as well as to DCA and pharmaceutically acceptable salts thereof, the carbon atoms of...
|
|
WO/2019/039767A2 |
The present invention provides a composition for adjusting biological tissue size, and a method for adjusting the size of biological tissue using said composition. A composition for adjusting biological tissue according to the present in...
|
|
WO/2018/232502A1 |
Polymeric transfection reagents for delivery of nucleic acids to cells, pharmaceutical compositions comprising same, and methods of preparing and using same are provided. A compound comprises polyethylenimine, a lipid selected from chole...
|
|
WO/2018/237350A1 |
The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I or pharmaceutically acceptable salt, hydrate, solvate or amino acid, sulfate or glucuronide conjugate, or prodrug ther...
|
|
WO/2018/223836A1 |
The present invention relates to a novel crystal form of a compound (I), a method for preparing same, and an application. Crystal form CS3, crystal form CS2, crystal form CS5, and crystal form CS8 of the compound (I) provided by the pres...
|
|
WO/2018/224736A2 |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof (I) wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or ...
|
|
WO/2018/213077A1 |
Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are...
|
|
WO/2018/201516A1 |
A compound and an application thereof for treatment of cataract. The structural formula of the compound is as shown in formula I. The compound of formula I, a prodrug thereof, or a pharmaceutically acceptable salt thereof, can be used to...
|
|
WO/2018/187804A1 |
The present invention relates to processes for preparing compounds of Formula (I) and compounds of Formula (II) or a pharmaceutically acceptable salt or solvate thereof. These compounds and pharmaceutical compositions are useful as FXR o...
|
|
WO/2018/175582A1 |
This disclosure relates to sporicidal compositions and uses thereof. The sporicidal compositions include one or more cationic steroidal antimicrobials (CSAs). The sporicidal compositions may be applied to an object to kill or deactivate ...
|
|
WO/2018/089373A9 |
Described herein protein steroid conjugates whereby a glucocorticoid compound is conjugated to a binding agent which is preferably an antibody. These are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to c...
|
|
WO/2018/103626A1 |
The present invention relates to the field of medicine, and particularly relates to a water-soluble allopregnenolone derivative, a pharmaceutical composition comprising the same, and use thereof in prevention or treatment of central nerv...
|
|
WO/2018/102369A1 |
Methods and systems for making onapristone (ONA) using acidic hydrolysis and dehydration with sulfuric acid in an alcoholic solution are provided.
|
|
WO/2018/068021A1 |
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...
|
|
WO/2018/064649A1 |
Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention ...
|
|
WO/2018/050815A1 |
The present invention relates to a compound of formula (I), in which R' represents a -(CRaRb)n-X-(CRcRd)m-[Y-(CReRf)o]t-NR9R10 group, and X and Y independently represent a -NR11- group, an –O- group or a divalent heterocyclic group com...
|
|
WO/2018/050814A1 |
The present invention relates to a compound of formula (I), in which R' represents a –(CRaRb)n-X-(CRcRd)m-[Y-(CReRf)o]t-NR9R10 group, and X and Y independently represent a -NR11- group, an –O- group or a divalent heterocyclic group c...
|
|
WO/2018/050099A1 |
Provided is a panaxdiol-type ginsenoside derivative having a structure as shown in formula I or formula II. Also provided is the use thereof in the preparation of a drug for preventing and treating atherosclerosis. The panaxdiol-type gin...
|
|
WO/2018/047090A1 |
The present invention pertains to a method of treating cancer or its relapse in mammals by employing platinum based compounds. More particularly, the present invention provides to enhance immunity in a mammal, using a compound of Formula...
|
|
WO/2018/035079A1 |
A class of cyanosteroid compounds that efficiently inhibit ghrelin acylation by ghrelin O-acyltransferase. The compounds have a steroid scaffold with α,β-unsaturated ketone in the A ring position such an a-cyanoenone. Exemplary compoun...
|
|
WO/2018/013613A1 |
Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a comp...
|
|
WO/2017/211820A1 |
The present invention relates to new and improved processes for the preparation of deoxycholic acid (DCA) and pharmaceutically acceptable salts thereof, as well as to novel intermediates useful for the preparation of DCA and pharmaceutic...
|
|
WO/2017/207648A1 |
The invention relates to a process for the preparation of obeticholic acid and derivatives thereof comprising: (a) olefination of a compound of formula (II) or a salt or solvate thereof to obtain a compound of formula (III) or a salt or ...
|
|
WO/2017/199033A1 |
The invention relates to compounds of general formula (I): wherein: R1,R2, R3, R4, R5, R6 and Y are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids which are useful in the treatment of conditio...
|
|
WO/2017/199039A1 |
The invention relates to a process for preparing a compound of general formula (Ia): wherein R2, Y, R4 and R5 are as defined herein. The invention also relates to certain compounds per se. The compounds are intermediates in the synthesis...
|
|
WO/2017/186135A1 |
Disclosed in the present invention are a compound and an application thereof for the treatment of cataracts. The structural formula of the compound is shown in formula I. The compound shown in formula I, a prodrug thereof, or a pharmaceu...
|
|
WO/2017/156418A1 |
This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the derm...
|
|
WO/2017/147159A1 |
The present invention provides compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
|
|
WO/2017/146440A1 |
The present invention relates to co-crystals of androstenone and vanillin, a method for preparing the same and a use of the same. The co-crystals of androstenone and vanillin of the present invention have a rigid lattice structure so as ...
|
|
WO/2017/112904A1 |
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...
|
|
WO/2017/106957A1 |
This invention provides lipid-linked prodrugs having structures as set out herein. Uses of such lipid-linked prodrug compounds for treatment of various indications, and methods for making and using lipid-linked prodrugs are also provided.
|
|
WO/2017/112909A1 |
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...
|
|
WO/2017/112902A1 |
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...
|
|
WO/2017/106214A1 |
Amorphous forms of onapristone and methods of making such amorphous forms are provided. Amorphous forms can be characterized by their X-ray powder diffraction patterns and other properties.
|
|
WO/2017/083794A1 |
Polyethylene glycol (PEG)-conjugated glucocorticoid prodrugs, methods of preparation, and use for the treatment of diseases and disorders are disclosed. In particular, PEG-conjugated dexamethasone compounds and methods of using them for ...
|
|
WO/2017/029664A1 |
A novel delivery system for drugs, and especially macromolecules such as proteins or oligonucleotides through biological membranes is provided, and specifically delivery of siRNA. The delivery system comprises conjugation of the macromol...
|
|
WO/2017/027396A1 |
The present application relates to a method of preparing compounds of Formula (A) or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof.
|
|
WO/2017/023694A1 |
This invention relates the use of Cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neop...
|
|
WO/2016/209732A1 |
The invention comprises compounds, methods of making, and methods of using. A group of polymer-cyclodextrin-lipid conjugates having a center backbone and three or four appended functional groups are disclosed, wherein one of the hydrophi...
|
|
WO/2016/205475A2 |
The application relates to compounds of formula (A): or a salt, solvate, ester, tautomer, amino acide conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, includin...
|
|
WO/2016/186821A1 |
Cationic steroidal antimicrobial (CSA) compounds having amide functionality and methods of manufacturing such CSA compounds. The CSA compound can be a compound of Formula (I), Formula (II), Formula (III), or a salt thereof: where R18 has...
|
|
WO/2016/184103A1 |
The present invention relates to a cholic acid modified glucosamine derivative and a preparation method and use therefor, the derivative being as shown in formula (I), wherein R1 is H or OH, R2 is H or OH, R3 is H, CH2 = CHCO- or CH2 = C...
|
|
WO/2016/173397A1 |
The present invention relates to a cholic acid derivative, and a preparation method and a medical use thereof. In particular, the present invention relates to a cholic acid derivative with the structure of formula (I), a stereoisomer, or...
|
|
WO/2016/173524A1 |
Disclosed in the present application are the compounds as shown in formulae I, II, III, IV or V, tautomers thereof, stereoisomers thereof or pharmaceutically acceptable salts thereof, and also disclosed is the use thereof in preparing dr...
|
|
WO/2016/173493A1 |
This disclosure is related to a sulfonylaminocarbonyl derivative of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the sulfonylaminocarbonyl derivatives of formula (I) and/or a phar...
|
|
WO/2016/154203A1 |
Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2. In one embodiment, a cytotoxic compound...
|
|
WO/2015/071657A9 |
Described herein are certain steroid derivative compounds, for example of formula (I): wherein X1, X2, X3 L, and Ar are as defined herein, pharmaceutical compositions comprising such compounds, the use of such compounds and compositions ...
|
|
WO/2016/113549A1 |
The invention relates to 3α-ethynyl, 3β-hydroxy, 5α-pregnan-20-oxime or a pharmaceutically acceptable salt thereof, which compounds and/or salts are useful as modulators of the mammal brain excitability via the gamma-5 aminobutyric ac...
|
